Home » Posts tagged 'تاميباروتان'
Tag Archives: تاميباروتان
SEARCH THIS BLOG

Blog Stats
- 2,671,869 hits
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- MHLW JAPAN, 厚生労働省
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- November 2019 (4)
- October 2019 (11)
- September 2019 (8)
- August 2019 (14)
- July 2019 (23)
- June 2019 (15)
- May 2019 (16)
- April 2019 (21)
- March 2019 (14)
- February 2019 (7)
- January 2019 (17)
- December 2018 (7)
- November 2018 (14)
- October 2018 (12)
- September 2018 (18)
- August 2018 (22)
- July 2018 (15)
- June 2018 (38)
- May 2018 (14)
- April 2018 (19)
- March 2018 (25)
- February 2018 (15)
- January 2018 (17)
- December 2017 (20)
- November 2017 (15)
- October 2017 (19)
- September 2017 (8)
- August 2017 (13)
- July 2017 (11)
- June 2017 (6)
- May 2017 (10)
- April 2017 (23)
- March 2017 (18)
- February 2017 (17)
- January 2017 (15)
- December 2016 (19)
- November 2016 (31)
- October 2016 (38)
- September 2016 (33)
- August 2016 (40)
- July 2016 (53)
- June 2016 (50)
- May 2016 (50)
- April 2016 (70)
- March 2016 (45)
- February 2016 (49)
- January 2016 (42)
- December 2015 (37)
- November 2015 (37)
- October 2015 (49)
- September 2015 (35)
- August 2015 (29)
- July 2015 (25)
- June 2015 (28)
- May 2015 (21)
- April 2015 (41)
- March 2015 (51)
- February 2015 (23)
- January 2015 (33)
- December 2014 (46)
- November 2014 (31)
- October 2014 (38)
- September 2014 (74)
- August 2014 (86)
- July 2014 (101)
- June 2014 (170)
- May 2014 (98)
- April 2014 (113)
- March 2014 (80)
- February 2014 (63)
- January 2014 (70)
- December 2013 (100)
- November 2013 (91)
- October 2013 (102)
- September 2013 (104)
- August 2013 (114)
- July 2013 (129)
- June 2013 (131)
- May 2013 (155)
- April 2013 (109)
- March 2013 (105)
- February 2013 (81)
Categories
- 0rphan drug status (172)
- accelerated approval (1)
- Acute myeloid leukaemia (1)
- African medicine (6)
- AIDS (7)
- Alzheimer's (3)
- ANALYTICAL (1)
- ANDA (5)
- Anthony crasto (38)
- antibacterial (1)
- ANTIBODIES (52)
- antiglaucoma (1)
- Antihypertensives (1)
- antimalarials (6)
- ARAB MEDICINE (5)
- Australia (1)
- AWARD (11)
- AYURVEDA (78)
- Biosimilar drugs (39)
- BLA (3)
- BLOGS (25)
- Breakthrough Therapy Designation (57)
- canada (4)
- cancer (141)
- cfda (6)
- china 2019 (1)
- china pipeline (34)
- CHINESE HERBS (24)
- chronic kidney disease (1)
- CLINICAL TRIALS (10)
- COMPANIES (81)
- conference (5)
- Contrast agent (7)
- CRL (1)
- CYSTIC FIBRIOSIS (1)
- Dengue (1)
- DIABETES (44)
- DNDi (1)
- Drug discovery (22)
- DRUG MARKETING (5)
- DRUG REVIEW (8)
- EMA (4)
- EU 2003 (1)
- EU 2005 (1)
- EU 2014 (4)
- EU 2015 (5)
- EU 2016 (4)
- EU 2017 (8)
- EU 2018 (5)
- EU PIPELINE (61)
- EU SUBMISSION (32)
- EXTENDED USE (1)
- FAST TRACK FDA (65)
- FDA 15 (4)
- FDA 2010 (2)
- FDA 2011 (1)
- FDA 2012 (6)
- FDA 2013 (6)
- FDA 2014 (52)
- FDA 2015 (39)
- FDA 2016 (23)
- FDA 2017 (58)
- FDA 2018 (52)
- FDA 2019 (35)
- Featured product (1)
- female sexual dysfunction (1)
- flow synthesis (14)
- FORMULATION (14)
- GAIN (1)
- Generating Antibiotic Incentives Now (1)
- GENERIC DRUG (105)
- GENERICS (21)
- glenmark (18)
- GLENMARK (16)
- GLIPTIN (1)
- GMP (10)
- gout (1)
- Greek medicine (3)
- Herbals (8)
- HOMEOPATHY (3)
- Human medicines European Public Assessment Report EPAR (2)
- Hypertension (1)
- idiopathic pulmonary fibrosis (3)
- IMPLANTS (2)
- IND 2017 (2)
- IND 2018 (3)
- IND Filed (2)
- Investigational device exemption (IDE) approval (2)
- JAPAN 2009 (1)
- JAPAN 2013 (1)
- JAPAN 2015 (2)
- japan 2017 (6)
- JAPAN 2018 (10)
- japan 2019 (8)
- Japan marketing (31)
- Japan pipeline (35)
- Korea (2)
- korea 2012 (1)
- korea 2016 (1)
- MAA (3)
- Malaria (16)
- MANUFACTURING (8)
- Market info (3)
- Marketing authorisation application EU (4)
- MEDICAL DEVICE (9)
- Monoclonal antibody (73)
- Nanotechnology (5)
- NCE (2)
- NDA (52)
- NDA JAPAN (3)
- Neutraceuticals (1)
- New Drug Application Resubmission FDA (5)
- NEW DRUGS (76)
- New drugs canada (5)
- New drugs china (6)
- New drugs EU (10)
- New drugs Japan (2)
- NEW USE DRUGS (1)
- Newzealand (2)
- NICE (2)
- NUCLEOTIDES (1)
- obesity (3)
- ocular hypertension (1)
- organic chemistry (12)
- Parkinson's disease (1)
- PATENT (93)
- PATENTS (82)
- Peptide drugs (22)
- PFIZER (1)
- PHASE 1 (70)
- PHASE 3 (1)
- PHASE1 (135)
- Phase2 drugs (241)
- Phase3 drugs (284)
- plaque psoriasis (1)
- POLYMORPH (10)
- Preclinical china (12)
- Preclinical drugs (117)
- Premture ejaculation (3)
- prime designation (1)
- Priority review (73)
- PROCESS (39)
- Promising clips (9)
- Psoriasis (1)
- QbD (2)
- QIDP (21)
- RADIOLABELLED (7)
- Rare disease (3)
- Regenerative medicine (4)
- Regulatory (74)
- Resubmission FDA (2)
- REVIEW (10)
- rheumatoid arthritis (2)
- Scottish Medicines Consortium (1)
- sex arousal (2)
- SFDA FAST TRACK (2)
- SINGAPORE (4)
- sNDA (12)
- sNDA JAPAN (2)
- spectroscopy (16)
- SPOTLIGHT (53)
- Stem cells (3)
- SYNTHESIS (10)
- TOXINS (1)
- Translational medicine (2)
- Transverse myletis (2)
- Tropical Disease Priority Review Voucher (1)
- UK (1)
- UNANI MEDICINE (2)
- Uncategorized (2,013)
- US HERBS (7)
- USFDA SUBMISSION (1)
- vaccine (9)
- veterinary (3)
- VITAMINS (2)
Recent Posts
- FDA approves novel treatment Oxbryta (voxelotor) to target abnormality in sickle cell disease November 26, 2019
- FDA approves new treatment XCOPRI (cenobamate tablets) for adults with partial-onset seizures November 22, 2019
- FDA approves first treatment Givlaari (givosiran) for inherited rare disease November 21, 2019
- Blarcamesine, ブラルカメシン , November 1, 2019
- LEUPRORELIN, リュープロレリン; October 25, 2019
- Penfluridol October 16, 2019
- Elacridar October 13, 2019
- Azeliragon October 10, 2019
- Afamelanotide, アファメラノチド , афамеланотид , أفاميلانوتيد , 阿法诺肽 , October 9, 2019
- Valacyclovir HCl October 3, 2019
- Flecainide acetate October 3, 2019
- Desvenlafaxine Succinate October 3, 2019
- METHYL DOPA October 3, 2019
- Vidofludimus October 1, 2019
- Edotreotide gallium Ga-68 October 1, 2019
ORGANIC SPECTROSCOPY

SUBSCRIBE

Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by EmailDR ANTHONY MELVIN CRASTO Ph.D
DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 year tenure till date Dec 2017, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 50 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 19 lakh plus views on New Drug Approvals Blog in 216 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc
Personal Links
- my sites on the net
- DR ANTHONY MELVIN CRASTO
- GOOGLE GROUP ORGANIC PROCESS DEVELOPMENT
- mixxt
- epernicus
- scipeople
- jimdo
- yolasite
- my cv
- slidestaxx
- wordpress blog
- ABOUT ME
- BRANDSITE
- SKILLPAGES
- Academia.edu
- DIIGO
- WIX
- WIX BLOG
- ISSUU
- SCRIBD
- BIZ
- GOOGLE BLOG
- APNACIRCLE
- Eurekamoments in Organic Chemistry
- Organic Chemistry by Dr Anthony
- Green Chemistry International
- Technology Transfer
- Stereochemistry
- Spectroscopy
- Polymorphism
- Reactions in Org Chem
- DR ANTHONY MELVIN CRASTO Ph.D
- Pharmaceuticals
- Medicinal chemistry
- Organic chemistry literature
- Patent related site
- Green chemistry
- Reagents
- R & D
- Molecules
- Heterocyclic chem
- Sourcing
- NEW DRUG APPROVALS
- WORLD DRUG TRACKER
- Green Chemistry International
- drug regulatory affairs international
- ORGANIC SPECTROSCOPY INTERNATIONAL
- ORGANIC SYNTHESIS INTERNATIONAL
- ALL ABOUT DRUGS
- ORGANIC CHEMISTRY INTERNATIONAL
- GOOGLE PLUS
- Drug Scaleup and Manufacturing International
- MEDICINAL CHEMISTRY INTERNATIONAL
- DRUG SYNTHESIS INTERNATIONAL
- SLIDESHARE
- DRUGS WEB
- GOOGLE SCHOLAR
- MEDCHEM-amcrasto
- ONE ORGANIC CHEMISTONE DAY
- DRUG PATENTS INTERNATIONAL
- MEDCHEM ANTHONY CRASTO
- MEDCHEM anthony crasto
- Gravatar
- ZING ME VIETNAM
- RESEARCH GATE
- AWARDS
Verified Services
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- MHLW JAPAN, 厚生労働省
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- November 2019 (4)
- October 2019 (11)
- September 2019 (8)
- August 2019 (14)
- July 2019 (23)
- June 2019 (15)
- May 2019 (16)
- April 2019 (21)
- March 2019 (14)
- February 2019 (7)
- January 2019 (17)
- December 2018 (7)
- November 2018 (14)
- October 2018 (12)
- September 2018 (18)
- August 2018 (22)
- July 2018 (15)
- June 2018 (38)
- May 2018 (14)
- April 2018 (19)
- March 2018 (25)
- February 2018 (15)
- January 2018 (17)
- December 2017 (20)
- November 2017 (15)
- October 2017 (19)
- September 2017 (8)
- August 2017 (13)
- July 2017 (11)
- June 2017 (6)
- May 2017 (10)
- April 2017 (23)
- March 2017 (18)
- February 2017 (17)
- January 2017 (15)
- December 2016 (19)
- November 2016 (31)
- October 2016 (38)
- September 2016 (33)
- August 2016 (40)
- July 2016 (53)
- June 2016 (50)
- May 2016 (50)
- April 2016 (70)
- March 2016 (45)
- February 2016 (49)
- January 2016 (42)
- December 2015 (37)
- November 2015 (37)
- October 2015 (49)
- September 2015 (35)
- August 2015 (29)
- July 2015 (25)
- June 2015 (28)
- May 2015 (21)
- April 2015 (41)
- March 2015 (51)
- February 2015 (23)
- January 2015 (33)
- December 2014 (46)
- November 2014 (31)
- October 2014 (38)
- September 2014 (74)
- August 2014 (86)
- July 2014 (101)
- June 2014 (170)
- May 2014 (98)
- April 2014 (113)
- March 2014 (80)
- February 2014 (63)
- January 2014 (70)
- December 2013 (100)
- November 2013 (91)
- October 2013 (102)
- September 2013 (104)
- August 2013 (114)
- July 2013 (129)
- June 2013 (131)
- May 2013 (155)
- April 2013 (109)
- March 2013 (105)
- February 2013 (81)
Categories
- 0rphan drug status (172)
- accelerated approval (1)
- Acute myeloid leukaemia (1)
- African medicine (6)
- AIDS (7)
- Alzheimer's (3)
- ANALYTICAL (1)
- ANDA (5)
- Anthony crasto (38)
- antibacterial (1)
- ANTIBODIES (52)
- antiglaucoma (1)
- Antihypertensives (1)
- antimalarials (6)
- ARAB MEDICINE (5)
- Australia (1)
- AWARD (11)
- AYURVEDA (78)
- Biosimilar drugs (39)
- BLA (3)
- BLOGS (25)
- Breakthrough Therapy Designation (57)
- canada (4)
- cancer (141)
- cfda (6)
- china 2019 (1)
- china pipeline (34)
- CHINESE HERBS (24)
- chronic kidney disease (1)
- CLINICAL TRIALS (10)
- COMPANIES (81)
- conference (5)
- Contrast agent (7)
- CRL (1)
- CYSTIC FIBRIOSIS (1)
- Dengue (1)
- DIABETES (44)
- DNDi (1)
- Drug discovery (22)
- DRUG MARKETING (5)
- DRUG REVIEW (8)
- EMA (4)
- EU 2003 (1)
- EU 2005 (1)
- EU 2014 (4)
- EU 2015 (5)
- EU 2016 (4)
- EU 2017 (8)
- EU 2018 (5)
- EU PIPELINE (61)
- EU SUBMISSION (32)
- EXTENDED USE (1)
- FAST TRACK FDA (65)
- FDA 15 (4)
- FDA 2010 (2)
- FDA 2011 (1)
- FDA 2012 (6)
- FDA 2013 (6)
- FDA 2014 (52)
- FDA 2015 (39)
- FDA 2016 (23)
- FDA 2017 (58)
- FDA 2018 (52)
- FDA 2019 (35)
- Featured product (1)
- female sexual dysfunction (1)
- flow synthesis (14)
- FORMULATION (14)
- GAIN (1)
- Generating Antibiotic Incentives Now (1)
- GENERIC DRUG (105)
- GENERICS (21)
- glenmark (18)
- GLENMARK (16)
- GLIPTIN (1)
- GMP (10)
- gout (1)
- Greek medicine (3)
- Herbals (8)
- HOMEOPATHY (3)
- Human medicines European Public Assessment Report EPAR (2)
- Hypertension (1)
- idiopathic pulmonary fibrosis (3)
- IMPLANTS (2)
- IND 2017 (2)
- IND 2018 (3)
- IND Filed (2)
- Investigational device exemption (IDE) approval (2)
- JAPAN 2009 (1)
- JAPAN 2013 (1)
- JAPAN 2015 (2)
- japan 2017 (6)
- JAPAN 2018 (10)
- japan 2019 (8)
- Japan marketing (31)
- Japan pipeline (35)
- Korea (2)
- korea 2012 (1)
- korea 2016 (1)
- MAA (3)
- Malaria (16)
- MANUFACTURING (8)
- Market info (3)
- Marketing authorisation application EU (4)
- MEDICAL DEVICE (9)
- Monoclonal antibody (73)
- Nanotechnology (5)
- NCE (2)
- NDA (52)
- NDA JAPAN (3)
- Neutraceuticals (1)
- New Drug Application Resubmission FDA (5)
- NEW DRUGS (76)
- New drugs canada (5)
- New drugs china (6)
- New drugs EU (10)
- New drugs Japan (2)
- NEW USE DRUGS (1)
- Newzealand (2)
- NICE (2)
- NUCLEOTIDES (1)
- obesity (3)
- ocular hypertension (1)
- organic chemistry (12)
- Parkinson's disease (1)
- PATENT (93)
- PATENTS (82)
- Peptide drugs (22)
- PFIZER (1)
- PHASE 1 (70)
- PHASE 3 (1)
- PHASE1 (135)
- Phase2 drugs (241)
- Phase3 drugs (284)
- plaque psoriasis (1)
- POLYMORPH (10)
- Preclinical china (12)
- Preclinical drugs (117)
- Premture ejaculation (3)
- prime designation (1)
- Priority review (73)
- PROCESS (39)
- Promising clips (9)
- Psoriasis (1)
- QbD (2)
- QIDP (21)
- RADIOLABELLED (7)
- Rare disease (3)
- Regenerative medicine (4)
- Regulatory (74)
- Resubmission FDA (2)
- REVIEW (10)
- rheumatoid arthritis (2)
- Scottish Medicines Consortium (1)
- sex arousal (2)
- SFDA FAST TRACK (2)
- SINGAPORE (4)
- sNDA (12)
- sNDA JAPAN (2)
- spectroscopy (16)
- SPOTLIGHT (53)
- Stem cells (3)
- SYNTHESIS (10)
- TOXINS (1)
- Translational medicine (2)
- Transverse myletis (2)
- Tropical Disease Priority Review Voucher (1)
- UK (1)
- UNANI MEDICINE (2)
- Uncategorized (2,013)
- US HERBS (7)
- USFDA SUBMISSION (1)
- vaccine (9)
- veterinary (3)
- VITAMINS (2)
Recent Comments
DR ANTHONY MELVIN CR… on AK 3280 | |
DR ANTHONY MELVIN CR… on Novobiocin, ノボビオシン; | |
DR ANTHONY MELVIN CR… on CT 1812 | |
DR ANTHONY MELVIN CR… on ACLIMOSTAT | |
DR ANTHONY MELVIN CR… on SRT 1720 |
SEARCH THIS BLOG
Tamibarotene, тамибаротен , تاميباروتان , 他米巴罗汀 ,
April 21, 2017 9:57 am / Leave a comment
Tamibarotene
тамибаротен , تاميباروتان , 他米巴罗汀 ,
94497-51-5 CAS
- Molecular FormulaC22H25NO3
- Average mass351.439 Da
4-(((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino)carbonyl)benzoic Acid, Tamibarotene
- Am 80
- Am 80 (pharmaceutical)
- Amnolake
- NSC 608000
- RR 110
Hisao Ekimoto, “TAMIBAROTENE CAPSULE PREPARATION.” U.S. Patent US20100048708, issued February 25, 2010.
Tamibarotene , a small molecule retinoic acid receptor alpha (RARα) agonists developed by Nippon Shinyaku, was approved in Japan for the treatment of acute promyelocytic leukemia (APL) in 2005. Recently, the drug was in clinical development for the treatment of acute myeloid leukemia (AML), myelodysplasia, pediatric solid tumor, and steroid-refractory
Tamibarotene (brand name: Amnolake), also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukaemia (APL) .[1] It is currently marketed only in Japan and early trials have demonstrated that it tends to be better tolerated than ATRA.[2] It has also been investigated as a possible treatment for Alzheimer’s disease, multiple myeloma and Crohn’s disease.[2][3]
Synthesis
The tetralin-based compound tamibarotene (7) has been tested as an agent for treating leukaemias.
Reaction of the diol (1) with hydrogen chloride affords the corresponding dichloro derivative (2). Aluminum chloride mediated Friedel–Crafts alkylation of acetanilide with the dichloride affords the tetralin (3). Basic hydrolysis leads to the primary amine (4). Acylation of the primary amino group with the half acid chloride half ester from terephthalic acid (5) leads to the amide (6). Basic hydrolysis of the ester grouping then affords (7).[4]
PAPER
Synthesis of Tamibarotene via Ullmann-Type Coupling
An effective process was developed for the preparation of tamibarotene via an Ullmann-type coupling in a nonpressurized l-proline/DMSO system. Notable features were the telescoping of reactions, avoiding environmentally hazardous materials, and an acceptable overall yield. The safe scalable process was validated on a 1 kg scale.
Mp 223–225 °C (lit. SEE BELOW mp 231–232 °C); 1H NMR (400 MHz, chloroform-d) δ 8.22 (d, J = 7.7 Hz, 2H), 7.97 (d, J = 7.7 Hz, 2H), 7.80 (s, 1H), 7.54 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 8.3 Hz, 1H), 1.70 (s, 4H), 1.31 (s, 6H), 1.29 (s, 6H); MS (ESI) m/z: 350.0 [M – H]−
…Journal of Medicinal Chemistry (1988), 31 (11), 2182-92
PAPER
Journal of Medicinal Chemistry (1988), 31 (11), 2182-92
PAPER
Chem. Pharm. Bull. 61(8) 846–852 (2013)
https://www.jstage.jst.go.jp/article/cpb/61/8/61_c13-00356/_pdf
References
- Jump up^ “Tamibarotene: AM 80, retinobenzoic acid, Tamibaro”. Drugs in R&D. 5 (6): 359–62. 2004. doi:10.2165/00126839-200405060-00010. PMID 15563242.
- ^ Jump up to:a b Miwako, I; Kagechika, H (August 2007). “Tamibarotene”. Drugs Today (Barc). 43 (8): 563–568. doi:10.1358/dot.2007.43.8.1072615. PMID 17925887.
- Jump up^ Fukasawa, H; Nakagomi, M; Yamagata, N; Katsuki, H; Kawahara, K; Kitaoka, K; Miki, T; Shudo, K (2012). “Tamibarotene: a candidate retinoid drug for Alzheimer’s disease” (PDF). Biological & Pharmaceutical Bulletin. 35 (8): 1206–1212. doi:10.1248/bpb.b12-00314. PMID 22863914.
- Jump up^ Y. Hamada, I. Yamada, M. Uenaka, T. Sakata, U.S. Patent 5,214,202 (1993).
![]() |
|
Names | |
---|---|
IUPAC name
4-[(1,1,4,4-tetramethyltetralin-6-yl)carbamoyl]benzoic acid
|
|
Identifiers | |
3D model (Jmol)
|
|
3564473 | |
ChEBI | |
ChemSpider | |
DrugBank | |
PubChem CID
|
|
UNII | |
Properties | |
C22H25NO3 | |
Molar mass | 351.45 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
////////////Tamibarotene, тамибаротен , تاميباروتان , 他米巴罗汀 ,
CC1(C)CCC(C)(C)C2=C1C=CC(NC(=O)C1=CC=C(C=C1)C(O)=O)=C2